Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Laser Photonics Announces Strategic Milestone on Advanced Laser Shield Anti Drone System (click to learn more) This emerging Bitcoin infrastructure company is building a vertically integrated model (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Tivic Health Systems Inc TIVC

Healthcare Medical Devices
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In... see more

Recent & Breaking News (NDAQ:TIVC)

Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod

ACCESS Newswire March 31, 2026

Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference

ACCESS Newswire March 27, 2026

Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome

ACCESS Newswire March 26, 2026

Tivic Reports Full Year 2025 Results

ACCESS Newswire March 25, 2026

Tivic Health CEO Letter to Shareholders

ACCESS Newswire March 24, 2026

Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET

ACCESS Newswire March 20, 2026

Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma

ACCESS Newswire March 4, 2026

Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10

ACCESS Newswire February 18, 2026

Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting

ACCESS Newswire January 28, 2026

Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

ACCESS Newswire January 26, 2026

Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference

ACCESS Newswire January 20, 2026

Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity

ACCESS Newswire January 12, 2026

Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines

ACCESS Newswire January 8, 2026

Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

ACCESS Newswire December 11, 2025

Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome

ACCESS Newswire November 18, 2025

Tivic Reports Third Quarter 2025 Financial Results

ACCESS Newswire November 14, 2025

Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)

ACCESS Newswire November 13, 2025

Tivic Expands Intellectual Property Portfolio

Business Wire November 10, 2025

Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

Business Wire November 6, 2025

Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

Business Wire October 22, 2025

Podcasts